With TransCode go­ing pub­lic, in­dus­try sur­pass­es $10B IPO mark; Galect­in's in­hibitor shows PhIb suc­cess in can­cer treat­ment

TransCode Ther­a­peu­tics has priced its IPO at $4 a share, and while that num­ber might be on the small­er end of IPOs this year, it sig­ni­fies the pass­ing of the $10 bil­lion mark for the in­dus­try.

With $10 bil­lion raised in pub­lic of­fer­ings so far this year, the biotech mar­ket is well on track to sur­pass its record to­tals for last year. (For more on biotech’s red-hot IPO space, book­mark our track­er here.)

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.